OncoMatch/Clinical Trials/NCT06393985
Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
Is NCT06393985 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Decitabine, venetoclax and blinatumomab for b-cell acute lymphoblastic leukemia.
Treatment: Decitabine, venetoclax and blinatumomab — This study aims to evaluate whether maintenance therapy with decitabine, venetoclax and blinatumomab could improve the 2-year progression free survival (PFS) of patients with philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who had recently received an allogeneic stem cell transplant and in measurable residual disease-negative remission.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR fusion (negative)
fusion gene negative
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: allogeneic hematopoietic stem cell transplant
who underwent an alloHSCT
Lab requirements
Blood counts
hematopoietic reconstitution, i.e., ANC ≥0.5 x 10^9/L, and platelets >20 x 10^9/L
Kidney function
Creatinine clearance ≥ 30 mL/min
Liver function
Total serum bilirubin ≤ 3 x upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 5 x ULN, aspartate aminotransferase (AST) ≤ 5 x ULN
Cardiac function
left ventricular ejection fraction ≥ 0.5 by echocardiography; no grade III/IV cardiovascular dysfunction (NYHA)
hematopoietic reconstitution, i.e., ANC ≥0.5 x 10^9/L, and platelets >20 x 10^9/L. Total serum bilirubin ≤ 3 x upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 5 x ULN, aspartate aminotransferase (AST) ≤ 5 x ULN. Creatinine clearance ≥ 30 mL/min. left ventricular ejection fraction < 0.5 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06393985 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received allogeneic hematopoietic stem cell transplant.
Does this trial require BCR?
Yes, BCR fusion is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify